Biopharmaceutical company CalciMedica said on Wednesday that it has dosed the first patients with its proprietary CM4620 under its Phase 2a clinical study for the treatment of acute pancreatitis.
The company said CM4620 is a potent and selective small molecule calcium release-activated calcium (CRAC). CRAC channels are found on many cell types, including immune cells and pancreatic acinar cells, where aberrant activation of these channels is thought to play a key role in the pathobiology of acute pancreatitis.
According to the company, CM4620 is patent protected and has been shown to be safe and well tolerated in Phase 1 safety studies.
This Phase 2a clinical study is intended to provide safety and tolerability data on CM4620 in acute pancreatitis patients with accompanying systemic inflammatory response syndrome (SIRS), as well as provide potential indications of beneficial effects.
In conjunction, the Phase 2a study is open-label in design and is being conducted in the US at several sites. It will evaluate two dose levels of CM4620 versus supportive care alone, concluded the company.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007